Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ret finger protein like 4A pseudogene 1 (RFPL4AP1)
- Target
- RFPL4AP1
- Molecular classification
- Processed pseudogene, Other (not a protein-coding gene, no receptor or enzyme activity)
01
Overview
Ret finger protein like 4A pseudogene 1 (RFPL4AP1) is a processed pseudogene located on human chromosome 19. Unlike protein-coding genes, pseudogenes like RFPL4AP1 lack the ability to encode functional proteins but may regulate gene expression post-transcriptionally, for example, by acting as microRNA sponges or competitive endogenous RNAs. Recent studies have shown that RFPL4AP1 is upregulated in gliomas, where elevated expression correlates with tumor grade, malignancy, immune infiltration, and poorer patient prognosis. Knockdown of RFPL4AP1 can inhibit the proliferation and invasion of glioma cells, suggesting a functional role for its RNA transcript in tumor biology. RFPL4AP1 is not targeted by any known drugs and is used primarily as a research biomarker.
- Other names
- Ret finger protein-like 4A pseudogene 1RFPL4AP1RFPL4A pseudogene 1HGNC:45138
02
Mechanism of action
Not applicable (no drugs known to target RFPL4AP1; its function, when implicated, is through RNA-mediated gene regulation instead of direct protein interactions)
03
Biological functions
Acts as a competitive endogenous RNA or microRNA sponge, modulating gene expression at the RNA level in certain contextsRegulation of ribosomal protein genes and possible roles in protein folding and posttranslational modificationMay influence cell proliferation, migration, and invasion in glioma cellsMay affect immune cell infiltration, especially M2-type macrophages in glioma
04
Disease associations
Cancer (especially glioma, with evidence for prognostic biomarker roles in GBM, LGG; other possible associations include DLBC, TGCT, THYM)Endocrine dysfunction and immune diseases (based on general pseudogene biology)
05
Safety considerations
Not applicable. As a pseudogene, there are no known direct therapeutic interventions or safety concerns associated with targeting RFPL4AP1. Indirect modulation of RNA regulatory networks could raise off-target effects if approached therapeutically, but no clinical interventions are described.
06
Interacting drugs
None known (as a pseudogene, RFPL4AP1 does not encode a protein and there are no known direct small molecule modulators or drugs targeting it)
07
Biomarkers
RFPL4AP1 expression levels are proposed as a prognostic biomarker for glioma
Beyond the preview
Go deeper on Ret finger protein like 4A pseudogene 1 (RFPL4AP1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ret finger protein like 4A pseudogene 1 (RFPL4AP1).